TransEnterix, Inc. (NYSEAMERICAN:TRXC)’s share price was down 13.9% during trading on Friday . The company traded as low as $0.37 and last traded at $0.38, approximately 5,971,004 shares changed hands during mid-day trading. An increase of 130% from the average daily volume of 2,597,725 shares. The stock had previously closed at $0.44.

A number of equities research analysts recently issued reports on TRXC shares. Royal Bank of Canada downgraded TransEnterix from an “outperform” rating to a “sector perform” rating and set a $1.00 price objective on the stock. in a research report on Thursday, August 8th. Zacks Investment Research downgraded TransEnterix from a “hold” rating to a “sell” rating in a research report on Thursday, October 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. TransEnterix presently has an average rating of “Hold” and an average target price of $2.62.

TransEnterix (NYSEAMERICAN:TRXC) last released its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.01). The business had revenue of $3.64 million during the quarter, compared to analyst estimates of $5.13 million.

Large investors have recently made changes to their positions in the company. First Trust Advisors LP grew its stake in shares of TransEnterix by 62.4% during the second quarter. First Trust Advisors LP now owns 706,949 shares of the medical instruments supplier’s stock valued at $961,000 after buying an additional 271,502 shares during the last quarter. Brown Advisory Inc. bought a new stake in shares of TransEnterix in the second quarter worth about $91,000. Alps Advisors Inc. grew its stake in shares of TransEnterix by 129.6% in the second quarter. Alps Advisors Inc. now owns 491,900 shares of the medical instruments supplier’s stock worth $669,000 after purchasing an additional 277,678 shares during the last quarter. A.R.T. Advisors LLC bought a new stake in shares of TransEnterix in the second quarter worth about $108,000. Finally, BlackRock Inc. grew its stake in shares of TransEnterix by 0.7% in the second quarter. BlackRock Inc. now owns 13,382,455 shares of the medical instruments supplier’s stock worth $18,200,000 after purchasing an additional 95,525 shares during the last quarter.

TransEnterix Company Profile (NYSEAMERICAN:TRXC)

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

Further Reading: Why investors pay attention to retained earnings

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.